Histone deacetylase (HDAC) inhibitors are a new group of anticancer agents that have a
potential role in the regulation of gene expression, induction of cell death, apoptosis and cell …

Cancer is as much an epigenetic disease as it is a genetic and cytogenetic disease. The
discovery that drastic changes in DNA methylation and histone modifications are commonly …

Histone deacetylase (HDAC) inhibitors are a new class of targeted anticancer agents.
Several HDAC inhibitors are in clinical trials and have shown significant activity against a …

Histone deacetylase (HDAC) inhibitors are emerging as an exciting new class of potential
anticancer agents for the treatment of solid and hematological malignancies. In recent years …

Histone deacetylase (HDAC) inhibitors are emerging as promising anticancer drugs.
Because aberrant activity and expression of HDACs have been implicated in various cancer …

Histone deacetylase inhibitors (HDACi) are a new class of antineoplastic agents with
demonstrable preclinical antitumor activity in both in vitro and in vivo studies in a wide range …

Recent reports have shown that pharmacological manipulation of chromatin remodeling by
histone deacetylase (HDAC) inhibitors, might develop into a potent and specific strategy for …

Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and
activities of transcriptional factors involved in both cancer initiation and progression through …

Histones are a family of nuclear proteins that interact with DNA, resulting in DNA being
wrapped around a core of histone octamer within the nucleosome. Acetylation/deacetylation …

Transformed cells, characterised by inappropriate cell proliferation, do not necessarily lose
the capacity to undergo growth arrest under certain stimuli. DNA, genetic information, is …